Chronic Obstructive Pulmonary Disease — IMT in Ventilatory Muscle Metaboreflex in COPD
Citation(s)
Aliverti A, Macklem PT How and why exercise is impaired in COPD. Respiration. 2001;68(3):229-39. Review.
Aliverti A, Macklem PT The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles. J Appl Physiol (1985). 2008 Aug;105(2):749-51; discussion 755-7. doi: 10.1152/japplphysiol.90336.2008. Epub 2008 Mar 20.
Dall'Ago P, Chiappa GR, Guths H, Stein R, Ribeiro JP Inspiratory muscle training in patients with heart failure and inspiratory muscle weakness: a randomized trial. J Am Coll Cardiol. 2006 Feb 21;47(4):757-63. Epub 2006 Jan 26.
Debigaré R, Maltais F The major limitation to exercise performance in COPD is lower limb muscle dysfunction. J Appl Physiol (1985). 2008 Aug;105(2):751-3; discussion 755-7. doi: 10.1152/japplphysiol.90336.2008a.
Levison H, Cherniack RM Ventilatory cost of exercise in chronic obstructive pulmonary disease. J Appl Physiol. 1968 Jul;25(1):21-7.
Mancini D, Donchez L, Levine S Acute unloading of the work of breathing extends exercise duration in patients with heart failure. J Am Coll Cardiol. 1997 Mar 1;29(3):590-6.
McConnell AK, Lomax M The influence of inspiratory muscle work history and specific inspiratory muscle training upon human limb muscle fatigue. J Physiol. 2006 Nov 15;577(Pt 1):445-57. Epub 2006 Sep 14.
Muthumala A Chronic heart failure and chronic obstructive pulmonary disease: one problem, one solution? Int J Cardiol. 2008 Mar 28;125(1):1-3. Epub 2007 Nov 26.
Neder JA, Andreoni S, Lerario MC, Nery LE Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res. 1999 Jun;32(6):719-27.
Neder JA, Andreoni S, Peres C, Nery LE Reference values for lung function tests. III. Carbon monoxide diffusing capacity (transfer factor). Braz J Med Biol Res. 1999 Jun;32(6):729-37.
Neder JA, Jones PW, Nery LE, Whipp BJ Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):497-504.
Neder JA The major limitation to exercise performance in COPD is inadequate energy supply to the respiratory and locomotor muscles vs. lower limb muscle dysfunction vs. dynamic hyperinflation. Interpretation of exercise intolerance in COPD requires an integrated, multisystemic approach. J Appl Physiol (1985). 2008 Aug;105(2):758-9. doi: 10.1152/japplphysiol.90336.2008e.
O'Donnell DE, Webb KA The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol (1985). 2008 Aug;105(2):753-5; discussion 755-7. doi: 10.1152/japplphysiol.90336.2008b.
Ørsted HC, Baerentsen K, Jensen VG, Kofod H, Thorn NA, Trolle D [On the origin and benefits of amniotic fluid. [Reprint of 1797 edition]. Published with comments and notes by the Danish society of the history of pharmacy. With historical contributions by K. Baerentsen, V. G. Jensen, H. Kofod, N. A. Thorn, D. Trolle]. Theriaca. 1977;18:1-107. Danish.
Pereira CA, Sato T, Rodrigues SC New reference values for forced spirometry in white adults in Brazil. J Bras Pneumol. 2007 Jul-Aug;33(4):397-406. English, Portuguese.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
